CA3131128A1 - Compounds and methods of deuterated xanomeline for treating neurological disorders - Google Patents
Compounds and methods of deuterated xanomeline for treating neurological disorders Download PDFInfo
- Publication number
- CA3131128A1 CA3131128A1 CA3131128A CA3131128A CA3131128A1 CA 3131128 A1 CA3131128 A1 CA 3131128A1 CA 3131128 A CA3131128 A CA 3131128A CA 3131128 A CA3131128 A CA 3131128A CA 3131128 A1 CA3131128 A1 CA 3131128A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- medicament
- milligrams
- formula
- trospium chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808954P | 2019-02-22 | 2019-02-22 | |
| US62/808,954 | 2019-02-22 | ||
| US201962936358P | 2019-11-15 | 2019-11-15 | |
| US62/936,358 | 2019-11-15 | ||
| PCT/US2020/019193 WO2020172516A1 (en) | 2019-02-22 | 2020-02-21 | Compounds and methods of deuterated xanomeline for treating neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3131128A1 true CA3131128A1 (en) | 2020-08-27 |
Family
ID=72145029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3131128A Pending CA3131128A1 (en) | 2019-02-22 | 2020-02-21 | Compounds and methods of deuterated xanomeline for treating neurological disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220144817A1 (enExample) |
| EP (1) | EP3927342A4 (enExample) |
| JP (1) | JP2022523355A (enExample) |
| CN (1) | CN113507928A (enExample) |
| AU (1) | AU2020226870A1 (enExample) |
| BR (1) | BR112021016457A2 (enExample) |
| CA (1) | CA3131128A1 (enExample) |
| WO (1) | WO2020172516A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021097427A1 (en) * | 2019-11-15 | 2021-05-20 | Karuna Therapeutics, Inc. | Xanomeline derivatives and methods for treating neurological disorders |
| WO2023061372A1 (zh) * | 2021-10-14 | 2023-04-20 | 南京迈诺威医药科技有限公司 | 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途 |
| US12269818B2 (en) | 2023-04-24 | 2025-04-08 | Terran Biosciences Inc. | Analogs of xanomeline |
| WO2025174424A1 (en) * | 2024-02-16 | 2025-08-21 | Terran Biosciences Inc. | Analogs of xanomeline, analogs of trospium, and methods of use thereof |
| CN119161338B (zh) * | 2024-11-25 | 2025-06-17 | 嘉兴安帝康生物科技有限公司 | 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2202776A1 (en) * | 1994-10-31 | 1996-05-09 | Franklin Porter Bymaster | Method for treating anxiety |
| JP2000501711A (ja) * | 1995-12-07 | 2000-02-15 | イーライ・リリー・アンド・カンパニー | 疼痛を処置する方法 |
| CN1777425A (zh) * | 2003-03-28 | 2006-05-24 | 阿卡蒂亚药品公司 | 用于疼痛控制的毒蕈碱性m1受体激动剂 |
| WO2010102218A1 (en) * | 2009-03-05 | 2010-09-10 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| ES2742728T3 (es) * | 2009-07-22 | 2020-02-17 | PureTech Health LLC | Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico |
| US10265311B2 (en) * | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| WO2012033956A1 (en) * | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
-
2020
- 2020-02-21 JP JP2021549216A patent/JP2022523355A/ja active Pending
- 2020-02-21 WO PCT/US2020/019193 patent/WO2020172516A1/en not_active Ceased
- 2020-02-21 AU AU2020226870A patent/AU2020226870A1/en not_active Abandoned
- 2020-02-21 US US17/310,735 patent/US20220144817A1/en not_active Abandoned
- 2020-02-21 BR BR112021016457-0A patent/BR112021016457A2/pt not_active Application Discontinuation
- 2020-02-21 CN CN202080014856.8A patent/CN113507928A/zh active Pending
- 2020-02-21 CA CA3131128A patent/CA3131128A1/en active Pending
- 2020-02-21 EP EP20759391.4A patent/EP3927342A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3927342A1 (en) | 2021-12-29 |
| EP3927342A4 (en) | 2022-11-16 |
| JP2022523355A (ja) | 2022-04-22 |
| WO2020172516A1 (en) | 2020-08-27 |
| CN113507928A (zh) | 2021-10-15 |
| US20220144817A1 (en) | 2022-05-12 |
| AU2020226870A1 (en) | 2021-09-09 |
| BR112021016457A2 (pt) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220144817A1 (en) | Compounds and methods of deuterated xanomeline for treating neurological disorders | |
| US11534434B2 (en) | Xanomeline derivatives and methods for treating neurological disorders | |
| CN102459270B (zh) | Janus激酶3的哌啶抑制剂 | |
| US20180311251A1 (en) | Ezh2 inhibitors for treating lymphoma | |
| CA2736370C (en) | Pyrazole carboxamide inhibitors of factor xa | |
| CN102892770A (zh) | 酪氨酸激酶三甲氧苯基抑制剂 | |
| BRPI0711228A2 (pt) | "composto, método de tratar um mamìfero que sofre de um doença ou de uma condição envolvendo as enzimas ciclooxiganase, composição farmacêutica, processo para e deuteração de um composto pelatroca de pelomenos um átomo de hidrogênio do dito composto com um átomo do deutério e processo para preparar m composto" | |
| CA2970948A1 (en) | Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator | |
| BRPI0711491A2 (pt) | composição, método de tratamento de um mamìfero que sofre uma doença ou de uma condição que envolve um receptor de benzodiazepina e composição farmacêutica" | |
| US20100125094A1 (en) | Pyrrolidinyl modulators of nicotinic acetylcholine receptors | |
| US20110257260A1 (en) | 3,4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor | |
| CA3229907A1 (en) | Deuterated empathogens | |
| CA3232827A1 (en) | Substituted phenylalkylamines | |
| CN118265710A (zh) | 吡啶化合物作为kv7.2增强剂 | |
| US20100075950A1 (en) | Phenylpropanone modulators of dopamine receptor | |
| CA3230779A1 (en) | Asymmetric allyl tryptamines | |
| EP4545534A1 (en) | Heterocyclic compound as taar1 ligand agonist | |
| US20100113478A1 (en) | Indolone modulators of 5-ht3 receptor | |
| US20180305298A1 (en) | Deuterated chlorokynurenines for the treatment of neuropsychiatric disorders | |
| HK40105893A (en) | Pyridine compounds as kv7.2 enhancers | |
| WO2023240205A1 (en) | Deuterated compounds | |
| KR20040015135A (ko) | 20-히드록시에이코사테트라엔산 생산 저해제 | |
| HK1238626A1 (en) | Preparation of deuterated piperidine inhibitors of janus kinase 3 | |
| NZ617347B2 (en) | Pentylenetetrazole derivatives | |
| CA2824626A1 (en) | 2-amino-naphthyridine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240221 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20241108 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20241126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241126 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250318 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250318 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250318 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250530 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250902 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251001 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251103 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260407 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260708 |